|Last Update: 06/18/13 - 4:00 PM EDT|
|YTD Performance: -2.58%|
|Previous Close: $91.32|
|52 Week Range: $81.82 - $119.54|
|Oustanding Shares: 195,146,634|
|Market Cap: 17,996,422,587|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||4||4||4||4|
|Growth Rate (Year over Year)||46.34%||32.55%||43.41%||12.65%|
Coverage of ALXN was started with a Neutral rating, Credit Suisse said. $110 price target. Company lacks near-term catalysts.
We see a lot of short squeezes as money rotates into laggard groups.
Just a natural change in leadership.
ALXN estimates were increased to reflect increased confidence in manufacturing now that the source of contamination has been identified. Price target goes to $123.
Upward momentum is lagging.
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
Shares of ALXN now seen reaching $120, UBS said. Estimates also lowerd on FDA warning letter and EU updates. Buy rating.
Charts of Actavis and Alexion show a combination of positive technical factors.
ALXN was downgraded from Buy to Neutral, Lazard Capital Markets said. $102 price target. Stock appears attractive, following a 30% decline.
Shares of ALXN now seen reaching $88, Jefferies said. Estimates also lowered on delay in Soliris launch. Hold rating.